INTRODUCTION

Top Abstract Introduction Materials & Methods Results Discussion References

Failure of oropharyngeal candidiasis (OPC) to respond to fluconazole has been noted in many institutions, usually in patients with far advanced human immunodeficiency virus (HIV) infection. The majority of HIV-infected patients with fluconazole-unresponsive OPC have CD4 counts below 50/mm³ and have received many months of azole therapy (24, 33). Resistance has arisen gradually, the infection has required higher and higher doses to respond, relapses have occurred more rapidly, and response to therapy has been progressively less complete. The gradual progression of resistance had suggested a series of mutations, and molecular analysis of sequential Candida albicans strains from such patients has supported this hypothesis (27, 29, 34, 39).

Several findings indicate that increased azole efflux is a major mechanism of resistance in C. albicans, Candida glabrata, and Saccharomyces cerevisiae. Studies of azole-resistant isolates have shown increased energy-dependent azole efflux in C. glabrata (11, 17, 22), decreased intracellular azole concentrations in C. albicans and C. glabrata (10, 11, 25), and increased expression of the C. albicans multidrug transporter genes CDR1, CDR2, and MDR1 (1, 27, 30, 38). Inactivation of the CDR1 gene in C. albicans (28) and PDR5 in S. cerevisiae (31) leads to increased fluconazole susceptibility and, in C. albicans, to increased intracellular fluconazole concentrations. Another mechanism of azole resistance has been postulated to be mutation of ERG3. The resultant defect in 5,6 desaturation is thought to prevent the cell from accumulating a toxic 14--methylergosta-8,24(28)-dien-3,6-diol in the presence of azole (14).

There is also evidence supporting the hypothesis that azole resistance may arise from chromosome duplications leading to increased expression of ERG11 (ERG16), the gene which codes for the azole target enzyme, lanosterol 14- demethylase (CYP51A1) (17, 35). Mutations in ERG11 that apparently alter substrate specificity may also cause azole resistance (12, 15, 29, 34). Identification of the key mutations which permit retention of lanosterol demethylation and yet block the effects of azoles are being defined (15, 29, 39).

Secondary resistance can arise during azole therapy by acquisition of a drug-resistant strain of the same or different species. C. glabrata is inherently more resistant to fluconazole than C. albicans and is found more commonly in patients receiving azoles (26). Fluconazole resistance can increase further in C. glabrata if the patient continues to receive fluconazole (37).

We describe a patient with advanced HIV infection whose oral candidiasis responded poorly to increasing doses of fluconazole. Oral cultures contained a C. glabrata strain that persisted and showed increased fluconazole resistance and increased fluconazole efflux. Using homology with the PDR5 and CDR1 genes, we cloned and sequenced a gene which appears to code for a multidrug transporter and showed increased transcription in the presence of fluconazole. The deduced amino acid sequence has the highest identity to the S. cerevisiae ATP-binding cassette transporter Pdr5p (Sts1p and Ydr1p) (4). Because we have not proven that the gene will confer the same phenotype as PDR5, we have chosen to designate the gene PDH1 (for pleomorphic drug resistance homolog) rather than PDR5. Many of the deduced amino acid sequences in Pdh1p are highly conserved in other fungal ABC transporters, including Yor1p and Snq2p (6) in S. cerevisiae, Cdr1p (23), Cdr2p (30) and Cdr3p (3) in C. albicans, bfr1⁺p in Schizosaccharomyces pombe (20), and Atrbp in Aspergillus nidulans (7). To date, the gene family coding for these proteins has not been studied in C. glabrata.

	MATERIALS AND METHODS

Top Abstract Introduction Materials & Methods Results Discussion References

Clinical isolates. A 45-year-old male infected with HIV type 1 with a CD4 count of 60/mm³ and a 4-year history of recurrent OPC was referred because of symptomatic thrush not responding to 200 mg of fluconazole given daily. Discrete and confluent plaques of thrush were evident on the hard palate and buccal mucosa. Microscopic examination of Gram-stained smears from his mouth showed yeast and pseudohyphae. Mouth culture grew C. albicans and C. glabrata. The patient was first treated with 400 mg of fluconazole given daily and seen every 2 weeks. After 4 weeks, he had achieved only a partial response, with at least 20% of the lesions remaining. Fluconazole was increased to 800 mg for 2 additional weeks, after which only a small patch remained on his buccal mucosa and oral symptoms had resolved. Therapy with 800 mg was continued an additional 2 weeks, after which no oropharyngeal lesions were detected. Esophagoscopy was not done. Prophylaxis with fluconazole (200 mg daily) was reinitiated, according to the study protocol. After 2 weeks, his OPC had returned.

Oral specimens. On each clinic visit, 2 weeks apart, the patient had a culture from the mouth placed on CHROMagar Candida (Hardy Diagnostics) (21). Five Candida colonies from each primary culture were subcultured on YEPD medium (1% yeast extract, 2% peptone, 2% glucose) at 30°C. Cells were suspended in 50% glycerol in water and stored at 80°C. Colonies were identified by germ tube formation in RPMI 1640 and then by use of the API 20C kit (BioMerieux Vitek).

RAPD. Both randomly amplified polymorphic DNA (RAPD) and a contour-clamped homogeneous electric field (CHEF) were used to show that the fluconazole-resistant isolates obtained later in the course were highly similar to the original C. glabrata strain obtained from this patient. RAPD was synthesized in a 50-µl reaction volume, using 25 ng of DNA, 5 mM Mg²⁺, 10 nmol of deoxynucleoside triphosphate (Boehringer Mannheim), 50 ng of primer, and 5 U of Taq DNA polymerase (Boehringer Mannheim) in 1× Taq buffer (Boehringer Mannheim). PCR was performed by the method of Lehmann et al. (16), using a Perkin-Elmer Cetus DNA thermal cycler model N801050, with 45 cycles, with 1 cycle consisting of 1 min at 94°C, 1 min at 36°C, and 2 min at 72°C, with a final elongation step at 72°C for 10 min. Following thermal cycling, the amplified DNA was separated by electrophoresis in a 2% (wt/vol) agarose (SeaKem GTG; FMC BioProducts) gel slab (11 by 14 by 1 cm) containing 0.5 µg/ml of ethidium bromide. A 1-kb DNA ladder (Gibco BRL) was included in each run. The primers used for RAPD were primer S (5'-GCGATCCCCA-3') (oligonucleotide 6 of reference 32), primer 6 (5'-AAGGATCAGA-3' (RP-2 of reference 16), and primer 7 (5'-CACATGCTTC-3') (RP4-2 of reference 16).

CHEF. Pulsed-field electrophoresis was performed with 0.8% chromosomal grade agarose (Bio-Rad) in 0.5× TBE (45 mM Tris, 45 mM borate, 1 mM EDTA; buffer pH 8.0) on gels (14 by 12.5 cm) using a Bio-Rad electrophoresis chamber with a CHEF-DR 11 Drive Module (Bio-Rad). Runs were done at 150 V with 120-s switch times ramped to 240 s over 25 h, followed by 180-s switch times ramped to 360 s over 20 h.

Cloning PDH1. Degenerate primers H12 and H13 were designed to amplify a 0.4-kb fragment, H1213, using genomic DNA of the C. glabrata NCCLS84 as the template. Sequences of H12 and H13, shown in Table 1, were chosen on the basis of amino acid sequences conserved in PDR5 and CDR1, including a part of Walker A and B motifs. Amplification was performed with Taq DNA polymerase (Boehringer Mannheim) and a mini-thermal cycler (MJ Research) with 25 cycles, with 1 cycle consisting of 1 min at 94°C, 80 s at 48°C, and 1 min at 72°C. The amplified fragment was extracted twice with equal volumes of phenol-chloroform and once with chloroform. Fragments were blunt ended with T4 DNA polymerase (New England Biolabs) treatment and inserted in pCR-Script SK(+) vector (Stratagene). The JM109 strain of Escherichia coli (Promega) was transformed with the constructed plasmid by heat pulses as described by the supplier. Clones were sequenced by using a rhodamine terminator sequencing reaction, run on an ABI Prism 377 (Perkin-Elmer). The base sequence was analyzed with GCG (Genetics Computer Group) software. When the sequence was confirmed to have sufficient identity to PDR5, the subcloned H1213 fragment was labeled with ³²P using random priming and used as a probe to screen an EcoRI-digested genomic library of the NCCLS84 strain of C. glabrata (Lambda Zap II library made by Stratagene). A 3.0-kb genomic fragment was identified, cloned into pBSK [Bluescript II SK (+); Stratagene] as CGlib18 and sequenced by the method described above. Since the sequence of the CGlib18 was shown to have high homology to the 5' end of the PDR5 gene, a downstream fragment was obtained by PCR, using NCCLS84 genomic DNA as the template. One primer (H22) was based upon 3' sequences from CGlib18. The other, a degenerate primer (H23) was based upon the S. cerevisiae PDR5 sequence (Table 1). A 1.3-kb fragment (H2223) was obtained, cloned into pCR-Script, and sequenced. A sense primer (H32) was derived from the 3' sequence of H2223, and a degenerate primer (H28) was obtained from S. cerevisiae PDR5 sequence. A 1.6-kb fragment (H3228) was obtained by PCR. H4546 was amplified from H3228. Southern blot of a Cla1 (New England Biolabs) digest of NCCLS84 genomic DNA using H4546 as a probe hybridized to a single 3.6-kb fragment. A size-selected Cla1 genomic library was then made from NCCLS84, ligating the 2.5- to 4.5-kb fragments into the Cla1 site of pBSK. Using H4546 as a probe, two 3.6-kb clones, Cla1-1 and Cla1-4, were identified by colony hybridization. Cla1-4 was sequenced in its entirety. This strategy is diagrammed in Fig. 1.

View larger version (11K): [in this window] [in a new window]   FIG. 1.   Cloned fragments of the C. glabrata PDH1 gene. Cloned genomic fragments CGlib18 and Cla1-4 are shown (the hatched areas indicate the ORFs). Five PCR subclones (H1213, H2223, H3228, H4546, and H3058) are shown, and each is aligned to the corresponding genomic sequence. Triangles at the end of PCR subclones show degenerate primers.

Probes for Southern and Northern blots. A 0.85-kb PCR fragment, H4546, was used for both Southern and Northern analyses. An ACT1 probe was prepared as previously published (8). A 25S rRNA-encoding sequence from C. albicans (18) was ³²P labeled as a probe for genes coding for rRNA (rDNA).

Southern analysis. C. glabrata genomic DNA was extracted from strain NCCLS84 as previously published (8), digested with a restriction enzyme, and used in gel electrophoresis. The gel was denatured (1 M NaCl, 0.5 M NaOH), neutralized (1 M Tris-HCl [pH 7.5], 1 M NaCl) and transferred to a nylon membrane (Hybond-N; Amersham). Chromosomal DNA run in CHEF gel was first depurinated with 0.25 M HCl at room temperature for 20 min and then transferred by the same procedure as for the digested genomic DNA. Probes were randomly labeled with [-³²P]dCTP (Amersham) using a Prime It II kit (Stratagene). The blot was hybridized with the probe at 65°C, washed once with washing solution 1 (2× SSC [1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate], 0.1% sodium dodecyl sulfate [SDS]) at room temperature, twice with washing solution 2 (0.2× SSC, 0.1% SDS) at room temperature, and then once at 65°C.

Northern analysis. RNA was prepared from C. glabrata cells after sufficient growth in YEPD medium at 30°C to provide an optical density at 600 nm of 1 to ~1.5. Cells were harvested and washed with RPMI 1640 medium with 300 mg of L-glutamine (Sigma) per liter, 0.165 M MOPS (morpholinepropanesulfonic acid) (Gibco BRL), and 2% glucose, pH 7.0. Cells were then rotated at 30°C for 4 h in the same RPMI 1640 medium with the addition of fluconazole (1 µg/ml). RNA was extracted from 50 mg of cells using the FastRNA Kit (Bio 101). Gel electrophoresis, blotting onto nylon membranes, and hybridization with ³²P-labeled probes were done by standard methods, and the blots were washed under the same conditions as those for the Southern blots.

Quantitation of signal intensities. Southern and Northern blots were exposed to Storage Phosphor Screens (Molecular Dynamics) for 3 h, and the screens were scanned with PhosphorImager 445 SI (Molecular Dynamics). The scanned images were quantitated with ImageQuant software (Molecular Dynamics). Quantitative volume data for the same-sized rectangular square on the blot image with each probe were used for analysis of the level of expression.

Other methods. Intracellular fluconazole concentrations were measured after 80 min of incubation in 100 nM [³H]fluconazole (714 GBq/mmol) at 37°C with shaking at 170 rpm in phosphate-buffered saline (22). Cultures were incubated with and without 100 µM carbonyl cyanide m-chlorophenylhydrazone (CCCP). This compound is a respiratory uncoupler which depletes intracellular stores of ATP. This concentration of CCCP did not decrease cell viability (data not shown). Specific activity of [³H]fluconazole was not sufficient to measure efflux from energy-deprived cells after glucose loading so this method was not used. MIC of fluconazole in microdilution broth was read after 48 h of incubation at 35°C. Methods of sterol analysis and antifungal susceptibility have been published elsewhere (8). Fluconazole levels in blood were performed by bioassay in the laboratory of Michael Rinaldi.

	RESULTS

Top Abstract Introduction Materials & Methods Results Discussion References

Studies of fluconazole resistance. Events that occurred to the patient during study are summarized in Table 2. The concentrations of fluconazole in blood were consistent with the prescribed dose. Of the five colonies selected from mouth cultures on each of the six patient visits, two C. glabrata and three C. albicans isolates were obtained for study on all visits except those on weeks 6 and 8, when only C. glabrata colonies were detected on the CHROMagar plates. The susceptibility of the C. glabrata isolates decreased to fluconazole and itraconazole, but not to amphotericin B, during fluconazole treatment. C. glabrata colonies obtained on the same throat culture had fluconazole MICs that were within 1 dilution of one another (data not shown). The C. albicans isolates had an initial fluconazole MIC of 8 µg/ml, much higher than our reference strain of C. albicans (B311), which had an MIC of 0.25 µg/ml. The last two C. albicans strains from this patient had an MIC of 32 µg/ml. Interest focused on C. glabrata because this species was isolated on every occasion, even on week 8 when no lesions were apparent and a sharp increase in azole resistance occurred after the first visit. The relative roles of C. glabrata and C. albicans in this patient's disease cannot be ascertained, but the absence of C. albicans during clinical response suggests this species was the major pathogen.

View larger version (75K): [in this window] [in a new window]   FIG. 2.   (A) RAPD gel analysis of C. glabrata DNA. Isolates were obtained at the start of the study (isolate 35a [lanes 2, 5, and 8]), at 2 weeks (isolate 36a [lanes 3, 6, and 9]), and at 4 weeks (isolate 37a [lanes 4, 7, and 10]). Primer S (lanes 2 to 4), primer 6 (lanes 5 to 7), and primer 7 (lanes 8 to 10) were used. A molecular ladder is shown in lane 1. (B) CHEF gel using isolates from weeks 0, 2, 4, 6, 8, and 10 (isolates 35a, 36a, 37a, 38a, 40a, and 43a, respectively) are shown in lanes 2 to 7, respectively. The Saccharomyces control is in lane 1.

View larger version (17K): [in this window] [in a new window]   FIG. 3.   Intracellular fluconazole concentrations. Isolates Y33.90 and Y33.91 were azole-susceptible and -resistant C. glabrata isolates from the previous report (22). Isolates 35a, 36a, 37a, 38a, 40a, and 43a were obtained at 0, 2, 4, 6, 8, and 10 weeks, respectively. Fluconazole accumulation without CCCP (white bars) and with CCCP (black bars) is shown. The standard errors are indicated by the error bars. OD600, optical density at 600 nm.

Sequence of PDH1. We obtained the complete PDH1 sequence from two genomic clones, CGlib18 and Cla1-4, which overlapped by 351 bp. Because CGlib18 and Cla1-4 overlapped but differed by one base, we sequenced the overlap area in another genomic clone, Cla1-1, and a PCR clone, H3058, that was directly amplified from genomic DNA with Vent DNA polymerase (New England Biolab) (Table 1 and Fig. 1). All the new clones gave the same sequence in the overlap area as Cla1-4. Analysis of the 6,225-base sequence revealed a 4,626-bp open reading frame (ORF) with 1,542 deduced amino acids. The deduced protein had a molecular mass of 175 kDa. There was no adenine at the 3 position 5' to the initiation ATG codon, although this has been invariant in the modest number of C. glabrata genes cloned so far: ERG3, ERG11, SNF1, TRP1, HIS3, URA3, and SEC14. No intron splice sites or alternative ORF was found. In the 623-bp 5'-flanking region, there was a TATAA sequence at 105 and CAAT sequences 365 and 136 from the ATG start site. Also in the putative 5' untranslated region was a 10-bp sequence identical to that described by Katzmann and coworkers for the S. cerevisiae PDR5 promoter (13). They described an 18-bp sequence which bound Pdr1p and Pdr3p and was critical for PDR5 expression (13) (Table 3). A palindrome that has been postulated to be a regulatory cis element in the PDR5 promoter was also found in the 5'-flanking sequence of PDH1 (19) (Table 3). The sequence TTTGCA is repeated four times between bases 468 and 502 5' to the ATG codon. The significance of this repeat is unknown. In the 3'-flanking sequence, two putative transcription termination signals were found: the AATAAA signal of Henikoff et al. (9) at +234 from the stop codon and the TAGN₂₈TAGTN₆TTT sequence of Zaret and Sherman (40) at +175. In both the C-terminal and N-terminal homologous halves of this molecule were ABC signatures and Walker motifs (36) that are highly conserved among ABC transporter proteins in S. cerevisiae (PDR5, SNQ2, and YOR1 [GenBank accession no. L19922, X66732, and Z73066, respectively]), C. albicans (CDR1, CDR2, and CDR3 [GenBank accession no. X77589, U63812, and U89714, respectively]) (Table 4). A Kyte-Doolittle hydropathy plot (window = 7) indicated six putative transmembrane domains in each of two homologous portions, similar to those reported in the transporter proteins listed in Table 4 (data not shown). Fasta search of the amino acid sequence (Fig. 4) retrieved PDR5 as the most similar peptide with 72.5% identity in the 1,526-amino-acid overlapping sequence. CDR1, a PDR5 homolog in C. albicans, was shown to have 53.9% identity in 1,527-amino-acid sequence overlap. SNQ2, a S. cerevisiae gene closely related to PDR5, had 39.1% identity in a 1,524-amino-acid overlap.

View larger version (106K): [in this window] [in a new window]   FIG. 4.   Comparison of the amino acid sequences of PDH1 and PDR5. For each pair of sequences, the top sequence is PDH1 and the bottom one is PDR5. Lines between the sequences indicate perfect matches of amino acids. Periods and colons between the sequences show similarity based on the Dayhoff table (30a) as described elsewhere (7a). There was 72.5% identity between the two sequences, with two gaps. Putative Walker A and B sites (double underlines) and putative ATP-binding sites (single underline) are indicated.

Southern and Northern analyses. Southern analysis with the H4546 probe showed a 1.8-kb band after EcoRV digestion. A single band of about 10 kb was found on PstI digestion with the same probe. Both findings are consistent with the restriction map obtained from the sequence (Fig. 5). Considering that PDH1 appeared as a single fragment of the anticipated size in Southern analysis, it was unlikely that the PDH1 gene had a duplicate copy. By Northern analysis, using phosphorimaging quantitation, transcription of PDH1 was increased from a PDH1/ACT1 ratio of 3.5 to 32.3 when the initial, more azole-susceptible strain, strain 35a, was incubated in fluconazole. In strain 40a, transcription was not further increased by fluconazole treatment, in that the PDH1/ACT1 ratio was unchanged at 26.6 without and 24.1 with fluconazole exposure. The PDH1/ACT1 ratio of strain 40a not exposed to fluconazole was 7.5 fold higher than that in strain 35a, indicating that PDH1 was upregulated in the more azole-resistant strain. In a separate Northern analysis, sequential isolates from the patient given increasing doses of fluconazole showed a progressive increase in PDH1 transcription in the absence of fluconazole (Fig. 6). The PDH1/ACT1 ratios in these isolates, isolates 35a, 36a, 37a, 38a, and 40a, were 2.3, 2.7, 2.8, 3.4, and 4.5, respectively.

View larger version (21K): [in this window] [in a new window]   FIG. 5.   Southern analysis and restriction map for PDH1 gene. EcoRV digestion of C. glabrata genomic DNA demonstrated a single 1.8-kb fragment in the Southern analysis as expected by the restriction map. PstI digestion showed a single fragment of about 10 kb. The sequenced area of the genome (white bar) and the PDH1 ORF (arrow) are shown.

View larger version (49K): [in this window] [in a new window]   FIG. 6.   Northern blots of PDH1 transcripts in our series of C. glabrata strains. Actin transcripts were used as controls for gel loading. The amount of PDH1 transcript relative to actin (ACT1) was higher in the azole-resistant strains (strains 36a, 37a, 38a, and 40a) than in the susceptible strain (strain 35a).

	DISCUSSION

Top Abstract Introduction Materials & Methods Results Discussion References

The patient when first seen had clinically apparent, symptomatic OPC despite a history of taking 200 mg of fluconazole each day and a blood level consistent with that history. Fluconazole susceptibility of the C. glabrata isolate from this patient was not different from our standard strain. It seems likely that the sudden appearance of azole resistance in serial isolates did not represent a strain change. RAPD patterns and all but the second CHEF band remained unchanged. Serial isolates of C. glabrata from the same patient often have shown variable bands with a size of >1.6 Mb, generally the top two bands. Variability has been attributed to changes in the copy number of rDNA in these bands (2). We also found rDNA in our two largest bands.

The change in azole MIC of the C. glabrata strains occurred when the fluconazole dose was increased. The more-resistant strains had a two- to threefold decrease in intracellular accumulation of fluconazole when incubated with radiolabeled drug. A metabolic inhibitor increased intracellular drug, indicative of active drug efflux. The failure of CCCP to increase intracellular concentrations to the level seen in the more-susceptible isolate may indicate that respiratory-independent mechanisms were also present.

Although decreased intracellular drug concentration may not fully explain a fourfold increase in fluconazole MIC, the change is approximately equal to the difference between the fluconazole-susceptible C. glabrata Y33.90 and the resistant strain Y33.91. The difference in intracellular concentration is also similar to that reported from five AIDS patients with susceptible and resistant C. albicans isolated from their oropharynx (27). The work reported here supports these prior observations but differs in some respects. Strains Y33.90 and Y33.91 gave different restriction fragment length polymorphism patterns and were considered different strains (11). The change in intracellular fluconazole concentrations reported here in a C. glabrata strain and in the four sets of C. albicans strains reported by Sanglard et al. (28) cannot be readily interpreted as simply strain differences because molecular typing methods detected only a modest difference. It appears more likely that increased drug efflux and resistance arose in the original strain. Cross-resistance to other azoles was found in our case, in the C. albicans-infected case reported by Hitchcock et al. (10), and in the four C. albicans-infected patients reported by Sanglard (28). Our report adds support to the concept that increased drug efflux is a major mechanism of azole resistance in C. glabrata. As noted in the introduction of this article, highly resistant isolates may have multiple mutations, particularly in the gene coding for the azole target enzyme, 14--demethylase. Increased azole resistance in our series of C. glabrata isolates may also reflect such mutations as well as the upregulation of ABC transporters.

It would be useful to identify the mutation which increased expression of PDH1 in the isolates obtained after isolate 35a. One possibility is increased PDH1 copy number. Marichal and coworkers found a 3.7-fold increase in the copy number of ERG11 (CYP51 and ERG16) in an azole-resistant C. glabrata, accompanied by an 8-fold increase in ERG11 mRNA (17). Almost four copies of the 740-kb chromosome were found, an aneuploid state which shifted towards euploidy during multiple subcultures. In our azole-resistant C. glabrata, there was no evidence of increased copy number on Southern blots or by probing the CHEF blot with PDH1 and ACT1. The latter gene was chosen for probing the CHEF blot because ACT1 resides on a 1.4-kb band (17), far larger than the chromosome containing PDH1. A more likely explanation for the increased expression in the azole-resistant isolates is that a mutation in a transcriptional regulator locus caused azole resistance by overexpressing ABC transporters (5). If regulation of PDH1 were analogous to regulation of PDR5, then fluconazole exposure may affect a regulatory locus which increases expression of a family of ABC transporter genes, including PDH1. The increase in PDH1 mRNA when isolate 35a was exposed to fluconazole is likely due to the same regulatory process. The 5'-flanking area of PDH1 contained a sequence similar to one of the PDR1/PDR3 binding sites which regulate PDR5 transcription in S. cerevisiae (13). PDR1/PDR3 coregulates not only PDR5 but also SNQ2 and YOR1, meaning that several genes may be upregulated by fluconazole exposure and that the fluconazole transporter may not be Pdh1p. Determining whether Pdh1p is a fluconazole transporter will require disrupting the gene or expressing the gene in a heterologous system, such as in a pdr5 S. cerevisiae mutant. Such studies are in progress. Whether or not PDH1 codes for an azole transporter, this gene provides a tool for studying the effects of azoles on regulatory loci controlling ABC transporter expression in C. glabrata.